CARLOS MENDEZ: Open Payments
NPI 1831404201 · JBSA LACKLAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,126 in 68 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $1,158 · 2025 $1,126
Food & beverage: $1,126
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 27 | $422 |
| AstraZeneca Pharmaceuticals LP | 12 | $215 |
| Bayer Healthcare Pharmaceuticals Inc. | 9 | $167 |
| Lilly USA, LLC | 10 | $118 |
| Abbott Laboratories | 3 | $72 |
| Merck Sharp & Dohme LLC | 1 | $24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
| Dexcom, Inc. | 1 | $20 |
| PFIZER INC. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $15 |
Products named: Kerendia, FARXIGA, Wegovy, AIRSUPRA, Ozempic, MOUNJARO, FREESTYLE LIBRE 3, JARDIANCE.
Industry payments across TX — which companies pay providers there.
